Angiotensin II-receptor antagonists: An overview

American Journal of Health-System Pharmacy

Volumn 57, Issue 13, 2000, Pages 1231-1241

  Dina, Raquel ^a,b   Jafari, Mahtab ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b NONE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Candesartan cilexetil; Eprosartan mesylate; Hypertension; Irbesartan; Losartan potassium; Mechanism of action; Telmisartan; Toxicity; Valsartan

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; AVALIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; CIMETIDINE; CYTOCHROME P450 2C9; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; EPROSARTAN; ETHINYLESTRADIOL; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLORTHIAZIDE PLUS IRBESARTAN; IRBESARTAN; KETOCONAZOLE; LEVONORGESTREL; LISINOPRIL; LOSARTAN POTASSIUM; RENIN; SARALASIN; TASOSARTAN; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; WARFARIN;

ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; COUGHING; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERANCE; GASTROINTESTINAL DISEASE; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0034235328     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.13.1231     Document Type: Article

References (89)

1. Burt VL, Whelton P, Roccella JR et al. Prevalence of hypertension in the US population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-13.
2. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens. 1994; 12:S1-5.
3. The 6th report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung, and Blood Institute National High Blood Pressure Education Program, 1997; NIH publication no. 98-4080.
4. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis. 1993; 22:745-54.
5. Timmermans PB, Chiu AT, Herblin WF et al. Angiotensin II receptor subtypes. Am J Hypertens. 1992; 5:406-10.
6. Neutel JM, Weber M, Pool J et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24-hours. Clin Ther. 1997; 19:447-57.
7. Simon TA, Gelarden T, Freitag SA et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardial. 1998; 82:179-82.
8. Lacourciere Y, Lefebvre J, Nakhle G et al. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens. 1994; 12(suppl):49S-53S.
9. Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II receptor antagonists. Pharmacother. 1996; 16: 849-60.
10. Timmermans PB, Carini DJ, Chiu AT et al. Nonpeptide angiotensin II receptor antagonists. Am J Hypertens. 1009; 3:599-604.
11. Frishman WH, Fozailoff A, Bin C et al. Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol. 1994; 34: 837-80.
12. Case DB, Wallace IM, Keim HJ et al. Usefulness and limitations of saralasin, a weak competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. Am J Med. 1976; 60: 825-36.
13. Wong PC, Price WA Jr, Chiu AT et al. Non-peptide angiotensin II receptor antagonists, XI: pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1991; 259:861-70.
14. Nelson E, Merrill D. Efficacy and safety of oral MK-954 (DuP753), an angiotensin receptor antagonist, in essential hypertension. J Hypertens. 1991; 9:468S-9S.
15. Christen Y, Waeber B, Nussberger J et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991; 83:1333-42.
16. Munafo A, Christian Y, Nussberger J et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992; 51: 513-21.
17. Yun CH, Lee HS, Rho JK et al. Oxidation of the angiotensin II receptor antagonist losartan (DUP753) in human liver microsomes. Role of cytochrome P4503A4 in formation of the active metabolite EXP3174. Drug Metab Dispos. 1995; 23:285-9.
18. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens. 1992; 5 (12, part2):247S-51S.
19. Brunner HR, Christian Y, Munafo A et al. Clinical experience with angiotensin II receptor antagonists. Am J Hypertens. 1992; 5 (12, part 2):243S-6S.
20. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995; 75: 793-5.
21. Burnier M, Rutschmann B, Nussberger J et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993; 22:339-47.
22. Tsunoda K, Abe K, Hagino T et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993; 6:28-32.
23. Gansevoort RT, de Zeeuw D, Shahinfar S et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens. 1994; 12:537-42.
24. Sweet CS, Bradstreet DC, Berman RS et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II receptor antagonist, in patients with essential hypertension. Am J Hypertens. 1994; 7:1035-40.
25. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II antagonist, in man. J Hypertens. 1997; 52:115-20.
26. Muller P, Flesch G, De Gasparo M et al. Pharmacokinetic and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997; 52:441-9.
27. 14C]-radiolabeled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997; 27(1):59-71.
28. Brookman LJ, Rolan PE, Palmer KR et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther. 1997; 62:272-8.
29. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996; 14:1147-51.
30. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996; 60:341-46.
31. Black HR, Graff A, Shute D et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin converting enzyme-inhibitor, lisinopril. J Hum Hypertens. 1997; 483-9.
32. Benz JR, Black HR, Graff A et al. Valsartan and hydrochlorothiazide in patients with essential hypertension, a multiple dose, double-blind, monotherapy. J Hum Hypertens. 1998; 12:861-6.
33. Dallas Hall W, Montoro R, Little John T et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest. 1998; 16:203-10.
34. Oparil S, Dyke S, Harris F et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996; 18:797-810.
35. Pool JL, Glazer R, Chiang YT et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999; 13:275-81.
36. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double blinded study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997; 37:101-7.
37. Brunner HR. The new angiotensin II receptor antagonist irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997; 10(12, part 2):311S-7S.
38. Marino MR, Langenbacher KM, Ford NF et al. Pharmacodynamics and pharmacokinetics of irbesartan in patients with mild to moderate hypertension. J Cardiovasc Pharmacol Ther. 1999; 4(2):67-75.
39. Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs. 1997; 54:885-902.
40. Pool JL, Guthrie RM, Littlejohn TW III et al. Dose-related antihypertensive effects of irbesartan in patients with mild-moderate hypertension. Am J Hypertens. 1998; 11:462-70.
41. Van de Meiracker AH, Admiraal PJJ, Kroodsma JM et al. Hemodynamic and biochemical effects of the ATI receptor antagonist irbesartan in hypertension. Hypertension. 1995; 25:22-9.
42. Reeves RA, Lin CS, Kassler-Taub K et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998; 31:1311-6.
43. Fogari R, Ambrosoli S, Corradi L et al. 24-hour blood pressure control by once daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens. 1997; 15:1511-8.
44. Marino MR, Langenbacher KM, Ford NF et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest. 1997; 14:385-91.
45. Howe P, Phillips P, Saini R et al. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999; 21:1373-96.
46. Larochelle P, Flack JM, Marbury TC et al. Effects and tolerability of irbesartan vs enalapril in patients with severe hypertension. Am J Cardiol. 1997; 80:1613-5.
47. Simon TA, Gelarden T, Freitag SA et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol. 1998; 82:179-82.
48. Timmermans PB, Carini DJ, Chiu AT et al. Angiotensin II receptor antagonists. Hypertension. 1991; 18(suppl 3):136S-42S.
49. Rief M, White WB, Fagan TC et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol. 1998; 82:961-5.
50. Sever P. Candesartan cilexetil: a new, long acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens. 1997; 11(suppl 2):S91-5.
51. Elmfeldt D, George M, Hubner R et al. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effects. J Hum Hypertens. 1997; 11(suppl 2):49S-53S.
52. Jonkman JHG, van Lier JJ, van Heiningen PNM et al. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens. 1997; 11(suppl 2):S31-5.
53. Trenkwalder P, Dahl K, Lehtovirta M et al. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press. 1998; 7:170-5.
54. Andersson OK, Neldman S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998; 7:53-9.
55. Bell TP, DeQuattro V, Lasseter KC et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol. 1999; 83:272-5.
56. Zanchetti A, Omboni S, Di Biago C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens. 1997; 11 (suppl 2):S57-9.
57. Oparil S. Candesartan cilexetil in combination with low dose hydrochlorothiazide is effective in severe hypertension. Am J Cardiol. 1999; 84(10A):35S-41S.
58. Oparil S, Levine JH, Zuschke CA et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol. 1999; 84:289-93.
59. Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension and special populations. Pharmacotherapy. 1999; 19(4, part 2):73S-8S.
60. Weber M, Clinical efficacy of eprosartan. Pharmacotherapy. 1999; 19(4, part 2):95S-101S.
61. Blum RA, Kazierad DJ, Tenero DM. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy. 1999; 19(4, part 2):79S-85S.
62. Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999; 19(4, part2):102S-7S.
63. Price DA, De'Oliveria JM, Fisher NDL et al. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. Hypertension. 1997; 30(part 1):240-6.
64. Weber M. Efficacy and safety of eprosartan in patients with essential hypertension: Results of an 8-week, double blind, placebo controlled, multicenter trial. J Hypertens. 1998; 16(suppl 2):S2-45.
65. Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of once and twice daily doses of eprosartan in essential hypertension. J Hypertens. 1997; 17:129-36.
66. Ponticelli C, for the Eprosartan Study Group. Comparison of the efficacy of eprosartan and enalapril in patients with severe hypertension. Am J Hypertens. 1997; 10:128A. Abstract.
67. Cox PJ, Bush BD, Gorycki PD et al. The metabolic fate of eprosartan in healthy subjects. Exp Toxicol Pathol. 1996; 48:340-1.
68. Kazierad DJ, Martin DE, Ilson B et al. Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol. 1998; 38:649-53.
69. Martin DE, Tompson D, Boike SC et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol. 1997; 43:661-4.
70. Meredith PA. Optimal dosing characteristics of the angiotensin I receptor antagonist telmisartan. Am J Cardiol. 1999; 84:7K-12K.
71. Karlberg BE, Lins LE, Hermansson K et al. Efficacy and safety of telmisartan, a selective ATI receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens. 1999; 17:293-302.
72. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther. 1998; 15:206-17.
73. Neutal JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract. 1999; 53(3):175-8.
74. McClellan KJ, Markham A. Telmisartan. Drugs. 1998; 56:1039-46.
75. Meredith P. Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartan. Am J Cardiol. 1999; 84:7K-12K.
76. Lacourciere Y. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract. 1999; 53(2):99-103.
77. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens. 1999; 17:293-302.
78. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs. 1997; 54:299-311.
79. Tikkanen I, Omvik P, Jensen H, for the Scandinavian Study Group. Comparison of the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertension. 1995; 13:1343-51.
80. Gradman AH, Arcuri KE, Goldberg Al et al. A randomized, placebo-controlled, double-blinded, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995; 25:1345-50.
81. Mallion JM, Boutelant S, Chabaux P et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit. 1997; 2(4):179-84.
82. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicenter study. Eprosartan Multinational Study Group. Curr Med Res. Opin. 1999; 15(1):15-24.
83. Mimran A, Ruilope RL, Kerwin L et al. A randomised double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range on enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens. 1998; 12:203-8.
84. Neutal JM, Frishman WH, Oparil S et al. Comparison of telmisartan with lisinopril in patients with mild-moderate hypertension. Am J Ther. 1999; 6(3):161-6.
85. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995; 13:1343-51.
86. Kassler-Taub K, Littlejohn T, Elliot W et al., for the Irbesartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild to moderate hypertension. Am J Hypertens. 1998; 11:445-53.
87. Soffer BA, Wright JT, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995; 26:112-7.
88. Cardinale V, ed. Drug Topics red book. Montvale, NJ: Medical Economics; 1999.
89. Pitt B, Segal R, Martinez FA et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349:747-52.